HIV

Some apparent modest associations not robust on sensitivity analyses.

Despite major advances in medical knowledge of the infection and in disease management, HIV still remains a big challenge worldwide, with its greatest burden in Africa.

Europe is sole global region with infection increases.

Fixed-dose triple-combination drug and doravirine get the nod.

In Europe, millions are unaware of their status.

Time from infection to diagnosis remains unchanged over 2 decades.

Results offer an opening to improving screening for both.

Option B ART use is high in this population.

GEMINI 1 and 2 results suggest noninferiority.

Outcomes are still poor in this population.

DEXA-Screening sollte Teil der Routineversorgung sein.

Überwachung der Lipide beim Wechsel der Behandlung der Patienten von Tenofovirdisoproxil zu Tenofoviralafenamid.

Professor Alexandra Calmy discusses where we are today regarding viral suppression, and presents data on the development of new drugs in 2018 and in the pipeline. She highlights the importance of people-centred care if we are to address the global need for better HIV treatment for a diverse population which includes the most marginalised.

Dr Zvi Cohen presents the phase 3 trial results of ibalizumab in heavily treatment experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen; ibalizumab was approved by the FDA in March 2018 for this patient population. Results from the Week 25 study (TMB-301) along with the Week 48 expanded access (completer) study (TMB-311) are discussed.